Annual donation made to Forever Angels baby home
Research Partnership has made a seasonal donation to its chosen charity, Forever Angels, this week of US$2,000.
Thanks to our employees, we also raised a further $1,850 for the charity through various fundraising activities, bringing our total donation this winter to $3,850. Read about our fundraisers here.Earlier this year Mark Jeffery and Mary Assimakopoulos, the Research Partnership's founders, travelled to the baby home to find out how our donations were being used and to help raise awareness of the charity's activities. (Watch the film here)Mary Assimakopoulos, Founding Director, comments, “Seeing firsthand the charity's work and the positive impact the home is having on the community made us see how vital it is that we continue to support Forever Angels. Our donations help provide better facilities for the many children who arrive at the home orphaned, sick and malnourished. Forever Angels gives children a better start in life and hope for a brighter future. I'm delighted to support the charity and I am extremely proud of our employees for devoting their time and effort this winter to raising extra funds." Val Lithgow, one of the charity’s trustees, told us, “Thank you so much for the amazing cheque you have sent us. It is an incredible amount, and we are so very grateful for your support.”For information on the…
What you 'Need to know' about BioPharma & Health care MR's Future
Pharma Market Research Report, December 2012
Published in the Pharma Market Research Report, December 2012 By Harriet Kozak, U.S. President The rising popularity of mobile devices and tablets amongst physicians presents a number of interesting opportunities for pharmaceutical marketers and, consequently, new challenges to MR. With 80% of U.S. physicians claiming to use a mobile device in their daily medical practices, pharma can now add value with Apps and internet tools to help doctors improve their productivity. Patients have also been keen to utilize Apps for education, support and to improve their health. For market researchers, I predict the challenge will be helping marketers understand precisely how audiences are engaging with Apps and other online resources and how their needs can best be served with these tools in the future. Physicians’ adoption of tablets has also meant that we have witnessed many pharma companies who have already moved, or are in the process of moving, their sales force from paper-based detail aids to ones given on iPad or tablet. No surprise, given the opportunities that these technologies offer for delivering more dynamic content. However, just like paper options, tablet detail aids must be fully tested and evaluated; we have recognized that effective MR allows any issues…
Celebrating 15 years!
We are currently celebrating the 15th anniversary since the company was founded in late 1997.
We can't believe we are now a team of over 100 people! Please watch our short film to see how we have grown. For every view we will make a donation to our charity, Forever Angels.
Sign up to receive Rapport Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here »
The top 25 of UK market research companies
The 2011 UK market research industry league tables have just been published by the MRS and place the Research Partnership in 25th position, up 7 places from 2010.
The tables reaffirm our position as the largest independent UK-based market research agency specialising in global healthcare. 2011 proved a milestone year for us as we completed our 1000th project and grew our headcount by around 40%.Whilst much of the market research industry appears to be stagnant or struggling, the Research Partnership has grown by 35%. We believe this is down to our continued commitment to delivering high quality outputs and innovation. For example we have been using mobile research as a means of delivering fresh insight, as demonstrated by our award winning paper at EphMRA 2012. And we have been applying creative thinking in our custom approaches (such as using quasi-qual and quant techniques) as a means of delivering more "bang for our customer's buck."As pharma looks to emerging markets for growth, we established an emerging markets team offering market expertise and workshops on the BRIC markets and beyond. And whilst we have always been reputed for our qualitative pedigree, we have developed a strength in conducting large-scale quantitative studies. Our quant specialists deliver high quality research and dashboard-style reporting outputs which have been well received by clients. We have also seen significant increase in demand for our syndicated…
Mike Mallinson joins the Access Partnership
Mike Mallinson has been appointed to lead the Access Partnership in the role of President.
Mike is a highly regarded pharma executive with over 30 years experience gained both agency and client-side, who has presented and published opinion papers on market access issues at many international meetings. Mike is supported by Rob White, Global Director of Market Access and Dr Shrinivas Rao Mukku, Global Director of Pricing and Reimbursement.Commenting on his appointment, Mike said, “I am delighted to be taking on this challenging new position. Our aim is for the Access Partnership to become the preferred commercial partner for delivering market access solutions, by gaining a reputation for delivering the best payer and key stakeholder insights and outstanding strategic consulting services. We recognise the access challenges facing our clients, particularly across the Tier 1 and Tier 2 Emerging Markets - having an Asia Pacific presence will mean we are well placed to meet our clients’ needs in this region.”The Access Partnership will be attending and exhibiting at ISPOR’s (International Society for Pharmacoeconomics and Outcomes Research) Annual European Congress at the ICC in Berlin 5-7 November, where they will be giving two podium and two poster presentations. Delegates are able to visit them on Stand 34 of the exhibition. Sign up to receive Rapport Rapport is our…